Source-grounded facts extracted from AETHLON MEDICAL INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
AETHLON MEDICAL INC reported financial results for the fiscal year ended March 31, 2026.
“Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment, today reported financial results for its fiscal year ended March 31, 2026, and provided an update on recent developments.”
AETHLON MEDICAL INC: Increased authorized shares of common stock from 6,000,000 to 100,000,000 (effective 2026-02-19).
“Our Board previously approved the amendment of our Articles of Incorporation, as amended, to increase the number of authorized shares of our common stock, par value $0.001 per share, from 6,000,000 shares to 100,000,000 shares (the “Articles Amendment”). As reported in Item 5.07 below, on February 19, 2026, our stockholders approved the Articles Amendment. The Articles Amendment was filed with the Secretary of State of the State of Nevada on February 19, 2026.”
AETHLON MEDICAL INC amended Amendment to Pre-Funded Common Stock Purchase Warrant with institutional investor valued at Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa (effective 2026-01-22).
“Also on January 22, 2026, the Company and the Purchaser entered into the Amendment to Pre-Funded Common Stock Purchase Warrant (the “PFW Amendment”). The PFW Amendment amends the terms of that certain Pre-Funded Common Stock Purchase Warrant by and between the Company and the Purchaser dated December 8, 2025 (the “Warrant”), as previously disclosed on the Current Report on Form 8-K filed by the Company on December 8, 2025. The PFW Amendment removed the requirement that Company obtain shareholder approval of issuance or exercise the pre-funded warrants under Nasdaq 5635 prior to those pre-funded warrants becoming exercisable. As a result, the pre-funded warrants are immediately exercisable.”
AETHLON MEDICAL INC amended Amendment to Securities Purchase Agreement with institutional investor valued at Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa (effective 2026-01-22).
“On January 22, 2026, Aethlon Medical, Inc. (the “Company”) and an institutional investor (the “Purchaser”) entered into the Amendment to Securities Purchase Agreement (the “SPA Amendment”). The SPA Amendment amends the terms of that certain Securities Purchase Agreement by and between the Company and the Purchaser dated December 5, 2025 (the “Securities Purchase Agreement”), as previously disclosed on the Current Report on Form 8-K filed by the Company on December 8, 2025. The SPA Amendment removed the requirement that Company obtain shareholder approval of issuance or exercise the pre-funded warrants under Nasdaq 5635 prior to those pre-funded warrants becoming exercisable. As a result, the pre-funded warrants are immediately exercisable. All other terms of the Securities Purchase Agreement remain unchanged.”
AETHLON MEDICAL INC entered into Warrant Inducement Agreement with a certain accredited and institutional holder (effective 2025-12-05).
“the Company entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with a certain accredited and institutional holder (the “Holder”) of the Company’s outstanding Common Stock Purchase Warrants issued on March 16, 2025 and September 4,2025”
AETHLON MEDICAL INC entered into Registration Rights Agreement with an institutional investor (effective 2025-12-05).
“the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchaser pursuant to which the Company has agreed to file a registration statement to register the resale of the Shares and the shares of Common Stock issuable upon exercise of the Common Warrants no later than thirty (30) calendar days following the date of the Securities Purchase Agreement”
AETHLON MEDICAL INC entered into Securities Purchase Agreement with an institutional investor (effective 2025-12-05).
“Aethlon Medical, Inc. (the “Company”) and an institutional investor (the “Purchaser”) entered into a securities purchase agreement (the “Securities Purchase Agreement”), pursuant to which the Company agreed to issue to the Purchaser, in a private placement (the “PIPE Offering”), (i) 596,452 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”) (or pre-funded warrants in lieu thereof) and (ii) 1,043,791 warrants to purchase shares of Common Stock at an exercise price of $4.03 per share (the “Common Warrants”).”
AETHLON MEDICAL INC issued up to a number of shares equal to 175% of the number of Warrant Shares issued of warrant to a certain accredited and institutional holder for exercise price per share equal to $4.03.
“par value $0.001 per share (“Common Stock”) (or pre-funded warrants in lieu thereof) and (ii) 1,043,791 warrants to purchase shares of Common Stock at an exercise price of $4.03 per share (the “Common Warrants”). The\ purchase price for each Share and the accompanying Common Warrant in the PIPE Offering is $4.03 per share. The PIPE Offering is expected to”
AETHLON MEDICAL INC issued 1,043,791 warrants to purchase shares of Common Stock of warrant to an institutional investor for $4.03 per share.
“(ii) 1,043,791 warrants to purchase shares of Common Stock at an exercise price of $4.03 per share”
AETHLON MEDICAL INC issued 596,452 shares of common stock to an institutional investor for $4.03 per share.
“par value $0.001 per share (“Common Stock”) (or pre-funded warrants in lieu thereof) and (ii) 1,043,791 warrants to purchase shares of Common Stock at an exercise price of $4.03 per share (the “Common Warrants”). The\ purchase price for each Share and the accompanying Common Warrant in the PIPE Offering is $4.03 per share. The PIPE Offering is expected to”
AETHLON MEDICAL INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“October 16, 2025, Aethlon Medical, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) and subject to the compliance and de”
AETHLON MEDICAL INC: Filed a Certificate of Change with the Nevada Secretary of State to effect a 1-for-10 reverse stock split of common stock, reducing authorized shares from 60,000,000 to 6,000,000, effective at 10:00 a.m. ET on October 16, 2025 (effective 2025-10-16).
“On October 14, 2025, Aethlon Medical, Inc., a Nevada corporation (the “Company”), filed a Certificate of Change (the “Certificate of Change”) pursuant to Section 78.209 of the Nevada Revised Statutes (“NRS”) with the Secretary of State of the State of Nevada authorizing a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”).”
AETHLON MEDICAL INC received a nasdaq extension granted notice regarding minimum bid price (rules 5810(c)(3)(A)).
“In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until December 24, 2024, to regain compliance with the Minimum Bid Requirement.”
AETHLON MEDICAL INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 7, 2025, the Company received a letter from Nasdaq (the “Extension Notice”) advising that the Company has been granted a 180-day extension, or until June 23, 2025, to regain compliance with the Minimum Bid Price”
Guy F. Cipriani departed as Chief Operating Officer at AETHLON MEDICAL INC.
“Guy F. Cipriani, Chief Operating Officer of the Company, has departed the Company.”
James B. Frakes was appointed as Chief Executive Officer at AETHLON MEDICAL INC.
“appointed James B. Frakes to serve as the Company’s permanent Chief Executive Officer”
AETHLON MEDICAL INC reported fiscal third quarter ended December 31, 2023 results: net income $3.6 million.
“On February 14, 2024, Aethlon Medical, Inc. issued a press release announcing its financial results for the quarter ended December 31, 2023.”
Guy F. Cipriani was appointed as Senior Vice President and Chief Operating Officer at AETHLON MEDICAL INC.
“Effective as of the Effective Date, Guy F. Cipriani, formerly Senior Vice President and Chief Business Officer of the Company, (i) was appointed as the Company’s Senior Vice President and Chief Operating Officer and (ii) resigned from the Board.”
James B. Frakes was appointed as Member of the Board of Directors at AETHLON MEDICAL INC.
“Effective as of the Effective Date, Mr. Frakes, Chief Financial Officer of the Company, was appointed as (i) Interim Chief Executive Officer of the Company, replacing Dr. Fisher, and (ii) a member of the Board of Directors of the Company”
James B. Frakes was appointed as Interim Chief Executive Officer at AETHLON MEDICAL INC.
“Effective as of the Effective Date, Mr. Frakes, Chief Financial Officer of the Company, was appointed as (i) Interim Chief Executive Officer of the Company, replacing Dr. Fisher, and (ii) a member of the Board of Directors of the Company”
Guy F. Cipriani resigned as Director at AETHLON MEDICAL INC.
“Resignation of Guy F. Cipriani as Director”
Charles J. Fisher, Jr., M.D. departed as Chief Executive Officer at AETHLON MEDICAL INC.
“(b) Departure of Charles J. Fisher, Jr., M.D. as Chief Executive Officer”
Charles J. Fisher, Jr. resigned as Director at AETHLON MEDICAL INC.
“Charles J. Fisher, Jr., M.D. has resigned from the board of directors of Aethlon Medical, Inc. (the “Company”), effective as of November 27, 2023”
AETHLON MEDICAL INC reported financial results for fiscal second quarter ended September 30, 2023.
“On November 14, 2023, Aethlon Medical, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.”
James B. Frakes was appointed as Director at AETHLON MEDICAL INC.
“Effective November 7, 2023, James B. Frakes, Chief Financial Officer of Aethlon Medical, Inc. (the “Company”), was appointed as (i) Interim Chief Executive Officer of the Company, replacing Charles J. Fisher, Jr. M.D., and (ii) a member of the Board of Directors of the Company (the “Board”).”
James B. Frakes was appointed as Interim Chief Executive Officer at AETHLON MEDICAL INC.
“Effective November 7, 2023, James B. Frakes, Chief Financial Officer of Aethlon Medical, Inc. (the “Company”), was appointed as (i) Interim Chief Executive Officer of the Company, replacing Charles J. Fisher, Jr. M.D., and (ii) a member of the Board of Directors of the Company (the “Board”).”
Guy F. Cipriani was appointed as Senior Vice President and Chief Operating Officer at AETHLON MEDICAL INC.
“Guy F. Cipriani, formerly Senior Vice President and Chief Business Officer of the Company, (i) was appointed as the Company’s Senior Vice President and Chief Operating Officer and (ii) resigned from the Board.”
Guy F. Cipriani resigned as Director at AETHLON MEDICAL INC.
“Guy F. Cipriani, formerly Senior Vice President and Chief Business Officer of the Company, (i) was appointed as the Company’s Senior Vice President and Chief Operating Officer and (ii) resigned from the Board.”
Charles J. Fisher, Jr., M.D. departed as Chief Executive Officer at AETHLON MEDICAL INC.
“(b) Departure of Charles J. Fisher, Jr., M.D. as Chief Executive Officer”
AETHLON MEDICAL INC shareholders approved Approve, pursuant to Nevada Revised Statutes (“NRS”) 78.2055, a reverse stock split of our common stock at a ratio in the range of 1-for-8 to 1-for-12, with such ratio to be determined in the discretion of the Board and with such reverse stock split to be effected at such time and date as determined at the 2023-09-15 meeting.
“Approve, pursuant to Nevada Revised Statutes (“NRS”) 78.2055, a reverse stock split of our common stock at a ratio in the range of 1-for-8 to 1-for-12, with such ratio to be determined in the discretion of the Board and with such reverse stock split to be effected at such time and date as determined by the Board in its sole discretion (but in no event later than October 5, 2023). The resolution was approved. Votes For Votes Against Abstentions 6,781,311 2,180,424 51,219”
AETHLON MEDICAL INC shareholders approved Elect six members of our Board of Directors at the 2023-09-15 meeting.
“Elect six members of our Board of Directors (the “Board”). All of the nominees were elected. Name Votes For Votes Against Abstentions Edward G. Broenniman 4,746,036 435,339 120,979 Guy F. Cipriani 4,859,449 322,920 119,985 Charles J. Fisher, Jr., MD 4,857,852 328,276 116,226 Nicolas Gikakis 4,859,443 321,710 121,201 Angela Rossetti 4,855,281 327,149 119,924 Chetan S. Shah, MD 4,870,838 316,233 115,283”
AETHLON MEDICAL INC reported first quarter ended June 30, 2023 results: net income approximately $3.3 million.
“As a result of the above factors, the company’s net loss increased to approximately $3.3 million in the three months ended June 30, 2023, from approximately $2.9 million in the three months ended June 30, 2022.”
Nicolas Gikakis was appointed as Director at AETHLON MEDICAL INC.
“appointed Nicolas Gikakis as (i) a member of the Board, and (ii) a member of the Nominating Committee.”
AETHLON MEDICAL INC reported financial results for fiscal year ended March 31, 2023.
“issued a press release announcing its financial results for the fiscal year ended March 31, 2023.”
AETHLON MEDICAL INC reported third quarter ended December 31, 2022 results: net income approximately $2,850,000.
“Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022”
AETHLON MEDICAL INC reported its second quarter ended September 30, 2022 results: net income approximately $3.8 million.
“As a result of the changes in revenues and expenses noted above, our net loss increased to approximately $3.8 million in the three months ended September 30, 2022, from approximately $2.0 million in the three months ended September 30, 2021.”
Angela Rossetti was appointed as Director at AETHLON MEDICAL INC.
“On March 24, 2022, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Ms. Angela Rossetti, effective as of April 1, 2022, as (i) a member of the Board, (ii) a member of the Audit Committee of the Board (the “Audit Committee”), (iii) a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), and (iv) a member of the Compensation Committee of the Board (the “Compensation Committee”).”
Sabrina Martucci Johnson resigned as Director at AETHLON MEDICAL INC.
“On March 23, 2022, Sabrina Martucci Johnson informed Aethlon Medical, Inc. (the “Company”) of her intent to resign as a member of the Board of Directors (the “Board”), effective as of April 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.